| 000 | 01682 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250516212911.0 | ||
| 264 | 0 | _c20150212 | |
| 008 | 201502s 0 0 eng d | ||
| 022 | _a1942-0870 | ||
| 024 | 7 |
_a10.4161/mabs.28841 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSzili, Dániel | |
| 245 | 0 | 0 |
_aSuppression of innate and adaptive B cell activation pathways by antibody coengagement of FcγRIIb and CD19. _h[electronic resource] |
| 260 |
_bmAbs _c |
||
| 300 |
_a991-9 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _ximmunology |
| 650 | 0 | 4 | _aAntigens, CD19 |
| 650 | 0 | 4 |
_aB-Lymphocytes _ximmunology |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 |
_aCytokines _ximmunology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunity, Innate _xdrug effects |
| 650 | 0 | 4 |
_aImmunoglobulin G _ximmunology |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _ximmunology |
| 650 | 0 | 4 |
_aLymphocyte Activation _xdrug effects |
| 650 | 0 | 4 |
_aMAP Kinase Signaling System _xdrug effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aReceptors, Antigen, B-Cell _ximmunology |
| 650 | 0 | 4 |
_aReceptors, IgG _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aToll-Like Receptor 9 _xantagonists & inhibitors |
| 700 | 1 | _aCserhalmi, Marcell | |
| 700 | 1 | _aBankó, Zsuzsanna | |
| 700 | 1 | _aNagy, György | |
| 700 | 1 | _aSzymkowski, David E | |
| 700 | 1 | _aSármay, Gabriella | |
| 773 | 0 |
_tmAbs _gvol. 6 _gno. 4 _gp. 991-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.4161/mabs.28841 _zAvailable from publisher's website |
| 999 |
_c23825711 _d23825711 |
||